| Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease M Masarone, V Rosato, M Dallio, AG Gravina, A Aglitti, C Loguercio, ... Oxidative medicine and cellular longevity 2018, 2018 | 598 | 2018 |
| NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome V Rosato, M Masarone, M Dallio, A Federico, A Aglitti, M Persico International journal of environmental research and public health 16 (18), 3415, 2019 | 131 | 2019 |
| Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage M Masarone, V Rosato, A Aglitti, T Bucci, R Caruso, T Salvatore, ... PLoS one 12 (6), e0178473, 2017 | 106 | 2017 |
| Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma M Persico, A Aglitti, R Caruso, A De Renzo, C Selleri, C Califano, ... Hepatology 67 (1), 48-55, 2018 | 89 | 2018 |
| Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals A Lleo, A Aglitti, A Aghemo, P Maisonneuve, S Bruno, M Persico, ... Digestive and Liver Disease 51 (2), 310-317, 2019 | 64 | 2019 |
| Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection E Lawitz, R Flisiak, M Abunimeh, ME Sise, JY Park, M Kaskas, ... Liver International 40 (5), 1032-1041, 2020 | 53 | 2020 |
| Viral hepatitis: Milestones, unresolved issues, and future goals P Torre, A Aglitti, M Masarone, M Persico World journal of gastroenterology 27 (28), 4603, 2021 | 50 | 2021 |
| Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA. LI. CA cohort derived estimate of amenability rate to immune checkpoint inhibitors … EG Giannini, A Aglitti, M Borzio, M Gambato, M Guarino, M Iavarone, ... Cancers 11 (11), 1689, 2019 | 49 | 2019 |
| Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis M Masarone, J Troisi, A Aglitti, P Torre, A Colucci, M Dallio, A Federico, ... Metabolomics 17, 1-13, 2021 | 45 | 2021 |
| Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis M Persico, V Rosato, A Aglitti, D Precone, M Corrado, AD Luna, F Morisco, ... Antiviral Therapy 23 (2), 129-138, 2018 | 45 | 2018 |
| Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets AG Gravina, M Dallio, M Masarone, V Rosato, A Aglitti, M Persico, ... Oxidative medicine and cellular longevity 2018, 2018 | 41 | 2018 |
| Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study M Persico, A Aglitti, M Milella, C Coppola, V Messina, E Claar, I Gentile, ... Liver International 39 (10), 1852-1859, 2019 | 39 | 2019 |
| High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma M Persico, A Aglitti, A Aghemo, M Rendina, A Lleo, A Ciancio, V Di Marco, ... Alimentary Pharmacology & Therapeutics 47 (12), 1705-1712, 2018 | 35 | 2018 |
| Hepatitis C virus infection in jail: difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program M Masarone, R Caruso, A Aglitti, C Izzo, G De Matteis, MR Attianese, ... Digestive and Liver Disease 52 (5), 541-546, 2020 | 24 | 2020 |
| HCV point‐of‐care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy M Persico, M Masarone, A Aglitti, C Armenante, A Giordano, A Guardiola, ... Liver International 39 (10), 1845-1851, 2019 | 17 | 2019 |
| Corrigendum to “Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease” M Masarone, V Rosato, M Dallio, AG Gravina, A Aglitti, C Loguercio, ... Oxidative Medicine and Cellular Longevity 2021, 1-1, 2021 | 8 | 2021 |
| The diagnostic conundrum in non-alcoholic fatty liver disease V Rosato, M Masarone, A Aglitti, M Persico Exploration of Medicine 1 (5), 259-286, 2020 | 7 | 2020 |
| Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1–6 infection M Persico, R Flisiak, M Abunimeh, M Sise, JY Park, M Kaskas, ... Journal of Hepatology 68, S292, 2018 | 7 | 2018 |
| Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma M Persico, A Aglitti, R Caruso, A De Renzo, C Selleri, C Califano, ... Hepatology 66, 589A-590A, 2017 | 7 | 2017 |
| Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort MG Quaranta, L Ferrigno, X Tata, F D'Angelo, M Massari, C Coppola, ... Digestive and Liver Disease 53 (12), 1603-1609, 2021 | 3 | 2021 |
